Judy Chou is the President and CEO of AltruBio, a clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases.
At AltruBio, Dr. Chou leads the development of PSG-1 immune checkpoint agonists, a first-in-class mechanism targeting chronically activated T cells in autoimmune diseases, with the mission of fundamentally resetting immune homeostasis rather than simply suppressing symptoms.
Before founding AltruBio, Dr. Chou served as Global Head of Biotech and Senior Vice President at Bayer Pharmaceuticals, where she oversaw a $3+ billion product portfolio and led over 2,000 employees across six sites. Under her leadership, Bayer launched products including Jivi and Eylea and transformed from traditional biologics to advanced therapies including cell and gene therapies.
Dr. Chou has spent over 25 years in drug development and biomanufacturing at Genentech, Pfizer, Medivation, and AbbVie, where she became broadly recognized for breakthrough technologies in high-throughput screening and accelerated product development.
.png)
.png)